INfections in Patients Treated With CAR-T

Starting soon

Conditions studied: Relapsed Multiple Myeloma, Refractory Multiple Myeloma, B-Cell Non-Hodgkin Lymphoma, Bloodstream Infections, CAR-T Cell Therapy

In brief

This study includes adults with multiple myeloma or B-cell lymphoma who were/will be treated with CAR-T cell therapy at the IRCCS Azienda Ospedaliero-Universitaria di Bologna. The aim is to better understand infections that may occur during the first year after CAR-T treatment, including how often they happen, their causes, and factors that may increase the risk. The study will use information from patients treated in the past and from newly enrolled patients. For some patients who develop fever after CAR-T therapy, a rapid molecular blood test will be used alongside standard tests to help identify bloodstream infections more quickly and support timely clinical care.

Key facts

Study ID

NCT07713511

Run by

IRCCS Azienda Ospedaliero-Universitaria di Bologna

People needed

290

Starts

2026-11-01

Expected to finish

2029-04-30

Last updated by the study team

2026-07-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of relapsed/refractory multiple myeloma or B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, not otherwise specified (DLBCL-NOS), high-grade B-cell lymphoma (HGBCL), primary mediastinal B-cell lymphoma (PMBCL), follicular lymphoma (FL) and mantle cell lymphoma (MCL)
• Receipt of CAR-T infusion at IRCCS AOUBo
• Age ≥18 years at the time of CAR-T infusion
• Signed informed consent

You may not qualify if…

• None

Where it is running

• IRCCS Azienda Ospedaliero-Universitaria di Bologna — Bologna, Italy, Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.